Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Open accessThe DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
Abstract
Checkpoint blockade immunotherapy targeting the PD-1/PD-L1 inhibitory axis has produced remarkable results in the treatment of several types of cancer. Whereas cytotoxic T cells are known to provide important antitumor effects during checkpoint blockade, certain cancers with low MHC expression are responsive to therapy, suggesting that other immune cell types may also play a role. Here, we employed several mouse models of cancer to investigate the effect of PD-1/PD-L1 blockade on NK cells, a population of cytotoxic innate lymphocytes that also mediate antitumor immunity. We discovered that PD-1 and PD-L1 blockade elicited a strong NK cell response that was indispensable for the full therapeutic effect of immunotherapy. PD-1 was expressed on NK cells within transplantable, spontaneous, and genetically induced mouse tumor models, and PD-L1 expression in cancer cells resulted in reduced NK cell responses and generation of more aggressive tumors in vivo. PD-1 expression was more abundant on NK cells with an activated and more responsive phenotype and did not mark NK cells with an exhausted phenotype. These results demonstrate the importance of the PD-1/PD-L1 axis in inhibiting NK cell responses in vivo and reveal that NK cells, in addition to T cells, mediate the effect of PD-1/PD-L1 blockade immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 (a.k.a. CD279) is expressed on activated T cells as well as other cells including but not limited to B cells, natural killer (NK) cells, and myeloid cells (Hsu et al., 2018; Nam et al., 2019).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hsu et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Cited by
Items 401–500 of 848
Chen, X., Chen, Y., Xin, Z., Lin, M., Hao, Z., Chen, D., He, T., Zhao, L., Wu, D., Wu, P., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149608 · Cited by 21
Ma, Y., Zhang, P., Bao, Y., Luo, H. B., Wang, J., Huang, L., & Zheng, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1093719 · Cited by 21
“suggested that NK cells are potential responders to PD-1/PD-L1 blockade and the efficacy of PD-1/PD-L1 blockade in some tumor mouse models depends on NK cell activity (34).”
BackgroundResultKiller instincts: natural killer cells as multifactorial cancer immunotherapy
Nersesian, S., Carter, E. B., Lee, S. N., Westhaver, L. P., & Boudreau, J. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269614 · Cited by 23
Innate lymphoid cells: A potential link between microbiota and immune responses against cancer
Panda, S. K., & Colonna, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.003 · Cited by 23
Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells
Lu, T., Chen, L., Mansour, A. G., Yu, M., Brooks, N., Teng, K., Li, Z., Zhang, J., Barr, T., Yu, J., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000177 · Cited by 21
“Immune evasion via PD-1/PDL1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 131: 1809–1819.”
BackgroundInfluentialPD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype
Wagner, A. K., Kadri, N., Tibbitt, C. A., van de Ven, K., Singh, S. B., Oliinyk, D., LeGresley, E. B., Campbell, N., Trittel, S., Riese, P., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105137 · Cited by 23
Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy
Liu, L., Wu, D., Qian, Z., Ying, J., You, Y., Wang, Y., Zhang, F., Ning, X., Mei, J., Iqbal, J., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02682-8 · Cited by 22
“Both CD8+ T cells and NK cells play essential roles in immunosurveillance to control tumor growth and metastasis, representing the adaptive and innate arms of antitumor immunity, respectively [61].”
Wang, X., Chai, Z., Li, Y., Long, F., Hao, Y., Pan, G., Liu, M., & Li, B. (2020) · Genes · doi:10.3390/genes11040435 · Cited by 22
“found that the natural killer cell response elicited by the PD-1/PD-L1 blockade played vital roles in the therapeutic effect of immunotherapy [47].”
BackgroundMussafi, O., Mei, J., Mao, W., & Wan, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.948405 · Cited by 21
Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells
Munari, E., Quatrini, L., Ciancaglini, C., Eccher, A., Bogina, G. S., Moretta, L., & Mariotti, F. R. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101660 · Cited by 37
Russo, G. L., Prelaj, A., Dolezal, J. M., Beninato, T., Agnelli, L., Triulzi, T., Fabbri, A., Lorenzini, D., Ferrara, R., Brambilla, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006833 · Cited by 22
Structure of PD1 and its mechanism in the treatment of autoimmune diseases
Rezayi, M., & Hosseini, A. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3827 · Cited by 20
“cells with a more stimulated phenotype express larger amounts of PD1 in comparison to NK cells with a fatigued phenotype.(14) Stimulated T cells express PD‐1 on their surface and emit IFN‐γ that encourage the expression of PD‐L1 in several tissues in a mouse”
BackgroundHarnessing natural killer cell effector function against cancer
Blunt, M. D., & Khakoo, S. I. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad031 · Cited by 20
“In accordance with this, murine models have shown that NK cells are required to mediate the full therapeutic efficacy of PDL-1 blockade [133] and iPSC-derived NK cells can co-operate with T cells in combination with anti-PD1 antibodies to control tumour growth in vivo [20].”
Abnormal Expression of c-Myc Oncogene in NK Cells in Patients with Cancer
Zakiryanova, G. K., Кустова, Е. А., Urazalieva, N. T., Baimuchametov, E. T., Nakisbekov, N. N., & Shurin, M. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030756 · Cited by 20
“Recent data confirming the importance of the inhibited NK cell functioning in vivo for cancer development and demonstrating that NK cells, in addition to T cells, mediate the effect of checkpoint blockade immunotherapy, reinforce our interests in NK cell-based cancer immunotherapy [16].”
BackgroundHanafy, M. S., Hufnagel, S., Trementozzi, A. N., Sakran, W., Stachowiak, J. C., Koleng, J. J., & Cui, Z. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-01933-y · Cited by 22
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses
Bu, X., Juneja, V. R., Reynolds, C. G., Mahoney, K. M., Bu, M. T., McGuire, K. A., Maleri, S., Hua, P., Zhu, B., Klein, S. R., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0493 · Cited by 22
“Likewise, PD-1 expression has been observed on NK cells and inhibits cytotoxic activity (12, 13).”
BackgroundKumar, V. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1895145 · Cited by 20
“Hence, NK cells also contribute to the immunotherapy targeting PD-1/PD-L1 interaction [333, 334].”
BackgroundPesini, C., Hidalgo, S., Arias, M. A., Santiago, L., Calvo, C., Ocáriz, M., Isla, D., Lanuza, P. M., Agustín, M. J., Gálvez, E. M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2096359 · Cited by 21
“Thus, the role of PD-1 in the physiological regulation of NK cell function is less characterized than in T cells, and the results are often not clear and/or contradictory.9–11 At present, PD-1 membrane expression (mPD-1) in healthy donors has been restricted to a subset of adaptive NK cells from CMV chronic infected d…”
BackgroundInfluentialLim, J. X., Lai, C., Mallett, G., McDonald, D., Hulme, G., Laba, S., Shapanis, A. G., Payne, M., Patterson, W., Alexander, M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2216587120 · Cited by 19
“Recent literature demonstrates that PD-1 can also enhance innate immunity within TME, but the initial innate immune population that is activated by PD-1 in exerting antitumor effect is unclear with some studies suggesting NK cells while others indicate myeloid cells (48, 49).”
Inducible CCR2+ nonclassical monocytes mediate the regression of cancer metastasis
Liu, X., Ren, Z., Tan, C., Nunez-Santana, F., Kelly, M. E., Yan, Y., Sun, H., Abdala‐Valencia, H., Yang, W., Wu, Q., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179527 · Cited by 21
“Our studies also explain why subcutaneous sites of B16 melanoma are more resistant to NK cell infiltration (60).”
Xu, Y., Xiao, Y. Z., Luo, C., Liu, Q., Wei, A., Yang, Y., Zhao, L., & Wang, Y. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106584 · Cited by 19
Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies
Horowitz, N. B., Mohammad, I., Moreno‐Nieves, U. Y., Koliesnik, I. O., Tran, Q., & Sunwoo, J. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.648580 · Cited by 20
“Blockade of these pathways in vivo can result in the reactivation of NK cells and ILCs, which may generate a strong antitumor response (105).”
BackgroundiPSCs in NK Cell Manufacturing and NKEV Development
Boyd-Gibbins, N., Karagiannis, P., Hwang, D. W., & Kim, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890894 · Cited by 19
Lanuza, P. M., Alonso, M. H., Hidalgo, S., Uranga-Murillo, I., García‐Mulero, S., Arnau, R., Santos, C., Sanjuán, X., Santiago, L., Comas, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890836 · Cited by 18
“One study has previously reported in cancer mouse models that the efficacy of PD-1/PDL-1 inhibitors partly depends on the presence of NK cells (17).”
BackgroundIL-33-ILC2 axis promotes anti-tumor CD8+ T cell responses via OX40 signaling
Okuyama, Y., Okajima, A., Sakamoto, N., Hashimoto, A., Tanabe, R., Kawajiri, A., Kawabe, T., & Ishii, N. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.11.006 · Cited by 18
Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments
Lee, S., & Kim, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417634 · Cited by 18
The Latest Look at PDT and Immune Checkpoints
Aebisher, D., Przygórzewska, A., & Bartusik‐Aebisher, D. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070430 · Cited by 22
“PD-1+ NK cells can be inhibited in killing cancer cells which means that PD-1 is an important checkpoint for NK cell activation, and PD-1 blockade can induce an antitumor response in these cells [112].”
BackgroundFife, C. M., Williams, J. M., James, F. R., Gregory, S., Andreou, T., Sunderland, A., McKimmie, C. S., Brownlie, R. J., Salmond, R. J., Heaton, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009522 · Cited by 19
“19 20 20 Recent studies have shown that NK cells are required for the efficacy of anti- PD-L1 monotherapy and combined PD-1/CTLA-4 (PC) blockade in subcutaneous tumor models, 14 21 while the role of NK cells in ICB in the context of the immune-specialized microenvironment of BrM remains unknown.”
IPSC‑derived NK cells for immunotherapy and therapeutic perspective (Review)
Wei, X., Chen, S., Liu, Y., Wei, N., Xiang, K., Qian, Q., & Xu, Z. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13587 · Cited by 18
“…enhance anti‑tumor efficacy by overcoming immunosuppression in the tumor microenvironment, ultimately improving anti‑tumor immune responses (136,137). currently, clinical trials employing iPSc‑nK cells in combination with mono‑ clonal antibodies mainly include FT596 and CD19t‑haNK…”
Zuo, Z., Xiong, J., Zeng, C., Jiang, Y., Xiong, K., Tao, H., & Guo, Y. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.625470 · Cited by 18
Grottoli, M., Carrega, P., Zullo, L., Dellepiane, C., Rossi, G., Parisi, F., Barletta, G., Zinoli, L., Coco, S., Alama, A., et al. (2022) · Cancers · doi:10.3390/cancers14205046 · Cited by 18
“Using several cancer mice models, Hsu and coworkers found that activated NK cells express PD-1 and that PD-1 engagement by PD-L1+ tumor cells potently suppress NK cell–mediated immunity to tumors [53].”
BackgroundMilling, L. E., Garafola, D., Agarwal, Y., Wu, S., Thomas, A., Donahue, N. D., Adams, J., Thai, N., Suh, H., & Irvine, D. J. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0247 · Cited by 30
“Finally, conflicting evidence exists surrounding the function of PD-1 as a putative exhaustion marker for NK cells (24, 43).”
SPHK1 promotes HNSCC immune evasion by regulating the MMP1-PD-L1 axis
Fang, Q., Chen, X., Cao, F., Xu, P., Zhao, Z., Lin, R., Wu, D., Deng, W., & Liu, X. (2024) · Theranostics · doi:10.7150/thno.102390 · Cited by 17
“The advancement of immune checkpoint inhibitors (ICIs) has ushered in a new era of cancer treatment, with PD-1 blockade therapy emerging as a breakthrough [31–32].”
Su, W., Li, Y., Yang, G., Zhao, Y., Zhou, X., Liu, G., Huang, X., Sohail, M., Hussaın, I., Liu, Q., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549587 · Cited by 19
NK cell and ILC heterogeneity in colorectal cancer. New perspectives from high dimensional data
Pietropaolo, G., Scarno, G., Stabile, H., Grimaldi, A., Gismondi, A., Santoni, A., & Sciumè, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100967 · Cited by 18
Martins, C. P., Silva, M. C., Rasbach, E., Singh, P. K., Itoh, Y., Williams, J. B., Statham, E., Meurer, A., Martinez, D. V., Brandenburg, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16776-1 · Cited by 18
Checkpoint Inhibitors in Acute Myeloid Leukemia
Damiani, D., & Tiribelli, M. (2023) · Biomedicines · doi:10.3390/biomedicines11061724 · Cited by 18
“Finally, NK cells show the upregulation of co-inhibitory receptors, such as PD1, Tim-3 and TIGIT, which correlate with poor function and resemble exhausted T cell status [85].”
BackgroundCell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
Li, X., Liu, Y., Gui, J., Gan, L., & Xue, J. (2024) · Advanced Science · doi:10.1002/advs.202400702 · Cited by 21
A novel endogenous CD16-Expressing Natural Killer Cell for cancer immunotherapy
Cheng, Z.-F., Li, H.-K., Yang, H., Lee, C.-Y., Tang, S.-W., Lin, Y., & Hsiao, S.-C. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.100935 · Cited by 17
Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment
Talaat, I. M., Elemam, N. M., Zaher, S., & Saber-Ayad, M. M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.955599 · Cited by 17
“Nevertheless, many tumors still develop resistance to ICB therapy, representing a potential therapeutic target (129).”
BackgroundIshiyama, K., Kitawaki, T., Otsuka, Y., Takaori‐Kondo, A., & Kadowaki, N. (2020) · Cancer Science · doi:10.1111/cas.14692 · Cited by 17
“Gender Agea (y) Treatment durationa (mo) CMV+ dasatinib (CMV+ DA) 30 18 M/ 12 F 55 (24-84) 17 (5-49) CMV− dasatinib (CMV− DA) 6 4 M/ 2 F 41 (31-52) 22 (8-58) CMV+ imatinib or nilotinib (CMV+ OTKI) 26 14 M/ 12 F 57 (32-84) 38 (7-119)”
Lin, A., Yao, J., Cheng, Q., Liu, Z., Luo, P., & Zhang, J. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s394894 · Cited by 16
“NK cells have recently been shown to enhance the efficacy of PD-1/PD-L1 immunotherapy.(46) Taken together, we hypothesize that the NOTCH signalling pathway also regulates NK cell activation via IFN-γ, thereby enhancing the effect of immunotherapy.”
BackgroundLi, S., Dai, W., Kam, N., Zhang, J., Lee, V. H.-F., Ren, X., & Kwong, D. L. (2024) · Cancers · doi:10.3390/cancers16071312 · Cited by 17
“Poly(I:C) enhanced ADCC effect on NPC cells after overnight treatment of immature NK cells from NPC patients [115].”
BackgroundZou, D., Xin, X., Xu, Y., Xu, H., Huang, L., & Xu, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36446 · Cited by 16
“Poorly infiltrated tumors can still exhibit good responses to ICIs, while highly infiltrated tumors may have poor responses [6,13,14].”
BackgroundHároníková, L., Zatloukalová, P., Kucerikova, M., Friedlová, N., Tylichová, Z., Kokas, F. Z., Hupp, T. R., Coates, P. J., & Vojtěšek, B. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00637-y · Cited by 18
“NK cells induce cell death in melanoma cells and their effectiveness was shown to be influenced by PD-L1 protein levels on tumor cells [52, 53].”
BackgroundTao, J., Zhang, J., Li, H., Zhou, Y., & Guan, C. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104553 · Cited by 17
Microenvironmental modulation of the developing tumour: an immune‐stromal dialogue
Jones, J. O., Moody, W. M., & Shields, J. D. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12773 · Cited by 18
Lu, S., Gao, J., Jia, H., Li, Y., Duan, Y., Song, F., Liu, Z., Ma, S., Wang, M., Zhao, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.707991 · Cited by 16
“At present, PD-1/PD-L1 inhibitors are combined with chemotherapy, radiotherapy, targeted drug therapy and other immunotherapies, which increases the number of CD8+ T cells in the tumor microenvironment of patients, destroys the immune escape of tumors, and enhances the anti-tumor effect of PD-1/PDL1 inhibitors (18–20).”
BackgroundInfluentialSun, Y., Zhou, J. H. S., & Jiang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842831 · Cited by 16
“2 Programmed Cell Death 1 (PD-1) Previous studies demonstrated that PD-1 expression is associated with disease progression in individuals with various tumors, and blockade of the immune checkpoint molecule PD-1/PD-L1 axis was shown to exert anti-tumor effects (41, 42).”
BackgroundThe Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia
Zafarani, A., Taghavi-Farahabadi, M., Razizadeh, M. H., Amirzargar, M. R., Mansouri, M., & Mahmoudi, M. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10449-2 · Cited by 16
Pan, W., Tao, T., Qiu, Y., Zhu, X. M., & Zhou, X. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104231 · Cited by 17
Guillamón, C. F., Martínez‐Sánchez, M. V., Gimeno, L., Campillo, J. A., Server-Pastor, G., Martínez-García, J., Martínez‐Escribano, J., Torroba, A., Ferri, B., Abellán, D., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0847 · Cited by 16
“Immunotherapy using NKcs expanded/activated ex vivo or stimulated in vivo with new immune-stimulatory agents could offer effective alternative treatments against recurrent/refractory tumors (40, 44).”
BackgroundLi, S., Geng, Z., Hong, S., Zhang, J., Yang, Y., Qin, W. D., Zhang, X., Zhuang, X., Huo, R., Han, S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1656063 · Cited by 24
Zhao, F., Zhu, J., Yu, R., Shao, T., Chen, S., Zhang, G., & Shu, Q. (2022) · Scientific Reports · doi:10.1038/s41598-022-24286-3 · Cited by 17
Chapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03001-2 · Cited by 16
“Indeed, PD-L1 was previously shown to suppress NK and CD8 T cell antitumor activity [41, 42].”
BackgroundZhang, J., Su, Y., Wang, X., Yao, X., & Du, J. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2001 · Cited by 17
Chen, S., Fei, Y.-R., Cai, X.-X., Wang, C., Tong, S., Zhang, Z.-Z., Huang, Y., Bian, D.-D., He, Y., & Yang, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1528248 · Cited by 19
Prognostic Biomarkers for Melanoma Immunotherapy
Twitty, C., Huppert, L. A., & DAUD, A. I. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0886-z · Cited by 16
Biolato, A. M., Filali, L., Wurzer, H., Hoffmann, C., Gargiulo, E., Valitutti, S., & Thomas, C. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.07.001 · Cited by 17
Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment
Carnevalli, L. S., Ghadially, H., & Barry, S. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633685 · Cited by 16
“Despite these findings, several studies have reported upregulation of PD-1 expression on NK cells in various mouse models (61, 62), and although blockade of PD-1/PD-L1 interaction has been shown to enhance activity of NK cells in vitro and in animal models (63), this is suggested to be mediated mainly through expressi…”
BackgroundDing, J., Zheng, Y., Wang, G., Zheng, J., & Chai, D. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188763 · Cited by 15
NK cell immunometabolism as target for liver cancer therapy
Wang, J., Liu, X., Jin, T., Cao, Y., Tian, Y., & Xu, F. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109193 · Cited by 15
Ziranu, P., Pretta, A., Pozzari, M., Maccioni, A., Badiali, M., Fanni, D., Lai, E., Donisi, C., Persano, M., Gerosa, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-31538-3 · Cited by 15
Promising immunotherapeutic targets in lung cancer based on single-cell RNA sequencing
Xue, Q., Peng, W., Zhang, S., Wei, X., Ye, L., Wang, Z., Xiang, X., Zhang, P., & Zhou, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148061 · Cited by 16
“The TdLN-TTSM cells express high levels of TCF, memory molecules (CD127, CD122, and CD62L), and low levels of PD-1 (24).”
BackgroundInfluentialBalasko, A. L., Kowatsch, M. M., Graydon, C. G., Lajoie, J., & Fowke, K. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-36468-8 · Cited by 19
Tenuta, M., Pandozzi, C., Sciarra, F., Campolo, F., Gelibter, A. J., Sirgiovanni, G., Cortesi, E., Lenzi, A., Isidori, A. M., Sbardella, E., et al. (2023) · Cancers · doi:10.3390/cancers15143592 · Cited by 16
“Interestingly, NK-depleted mice showed a completely ineffective PD-1/PD-L1 blockade [21].”
BackgroundOverview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell
Yang, C., Li, Y., Yang, Y., & Chen, Z. (2020) · Journal of Immunology Research · doi:10.1155/2020/8459496 · Cited by 17
“The 2018 Nobel Prize in Physiology and Medicine was also awarded to the discoverers of cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PD1) [61, 62].”
Sugii, N., Matsuda, M., Okumura, G., Shibuya, A., Ishikawa, E., Kaneda, Y., & Matsumura, A. (2020) · Cancer Science · doi:10.1111/cas.14721 · Cited by 15
Kim, N., Lee, D.-H., Choi, W. S., Yi, E., Kim, H., Kim, J. M., Jin, H., & Kim, H. S. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.214 · Cited by 17
Immunosenescence: Molecular Mechanisms, Diseases, and Therapeutic Innovations
Gong, N., Pan, X., Deng, Y., Che, J., Bao, J., Wang, M., Xu, C., Liu, X., & Shi, Y. (2025) · MedComm · doi:10.1002/mco2.70515 · Cited by 18
“Besides with expressing heterogeneous immunological checkpoint molecules to brake immune reaction of T cells or NK cells (e.g., PD-L1, Tim-3), intratumoral MDSCs also secrete SASPs like indoleamine 2,3-dioxygenase and Arg1 to recruit Treg cells [376–379].”
Ahmadnia, A., Mohammadi, S., Yamchi, A., Kalani, M. R., Farazmandfar, T., Khosravi, A., & Memarian, A. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040183 · Cited by 15
Pan, Y., Xue, Q., Yang, Y., Shi, T., Wang, H., Song, X., Luo, Y., Liu, W., Ren, S., Cai, Y., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101590 · Cited by 20
Rosenbaum, S. R., Hughes, C. J., Fields, K. M., Purdy, S. C., Gustafson, A. L., Wolin, A. R., Hampton, D., Shrivastava, N., Turner, N., Danis, E. P., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt0504 · Cited by 14
“Emerging evidence also suggests that NK cells positively contribute to the response to Programmed cell death 1 (PD-1)/PD-L1 inhibitors ( 105 ), which are already approved by the Food and Drug Administration for use in metastatic TNBC. Understanding how tumor-intrinsic mechanisms inhibit NK…”
Immunomodulatory effects of photothermal therapy in breast cancer: advances and challenges
Chen, L., Zhang, H., Hou, Y., Yunlong, W., & Feng, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544693 · Cited by 17
Bhola, N. E., Njatcha, C., Hu, L., Lee, E. D., Shiah, J. V., Kim, M., Johnson, D. E., & Grandis, J. R. (2021) · Head & Neck · doi:10.1002/hed.26827 · Cited by 15
A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen
Yin, J., Wen, M., Cheng, J., Hu, L., Yang, L., Chang, X., Zhou, Z., Li, H., Liu, Y., & Li, J.-B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.712466 · Cited by 15
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
Long, Y., Yu, X., Chen, R., Tong, Y., & Gong, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910704 · Cited by 16
Park, H., Kim, Y. M., Jung, J. S., Ji, W., Lee, J. C., & Choi, C. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14523 · Cited by 15
“Pembrolizumab, which blocks PD-1 activity, could enhance NK cell activity and the cytotoxic properties of NK cells.(12) A previous RCT showed that the addition of allogeneic NK cells to pembrolizumab therapy enhanced the anticancer efficacy of pembrolizumab; OS and PFS were improved.”
BackgroundDonini, C., Galvagno, F., Rotolo, R., Massa, A., Merlini, A., Scagliotti, G. V., Novello, S., Bironzo, P., Leuci, V., & Sangiolo, D. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02363-2 · Cited by 15
“PD-1 is also found on the membrane of NK cells [38] and innate lymphoid cells (ILCs).”
BackgroundKedia-Mehta, N., Choi, C., McCrudden, A., Littwitz-Salomon, E., Fox, P. G., Gardiner, C. M., & Finlay, D. K. (2019) · PubMed · doi:10.20900/immunometab20190014 · Cited by 14
“…evidence that NK cells contribute to the therapeutic effect of checkpoint inhibitor therapies as some tumour infiltrating NK cells can express PD-1, but it is tempting to speculate that increased T cell production of IL2 within the tumour also makes an important contribution to this effect [49].”
B7-H3 in glioblastoma and beyond: significance and therapeutic strategies
Babič, D., Jovčevska, I., & Zottel, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1495283 · Cited by 16
Recent advances in the study of immune checkpoint inhibitor-associated pneumonia
Feng, X., Li, G., & Li, C. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104591 · Cited by 16
Wu, S., Ho, C., Yang, J. C., Yu, S., Lin, K., Lin, S., Liao, B.-C., Yang, C., Lin, Y., Yu, C., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70149 · Cited by 14
Fischer, P., Schmid, M., Ohradanova‐Repic, A., Schneeweiss, R., Hadatsch, J., Grünert, O., Benedum, J., Rohrer, A. M., Staudinger, F., Schatzlmaier, P., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07873-w · Cited by 14
“Prior to irradiation, cell culture fl asks were fi lled air-bubble free with unsupplemented medium to accommodate the vertical fl ask positioning in both irradiation work fl ows, which was replaced immediately after irradiation with fresh, supplemented medium.”
Xing, C., Duan, T., Li, L., Chen, L., Zhang, P., Du, Y., Liu, S., Annaparthi, N., Wang, S., Chen, Q., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads3530 · Cited by 16
“Beside T cells, PD-1 Ab therapy can also modulate other key immune cells in the tumor microenvironment, such as natural killer cells and macrophages, and mediate the antitumor immunity ( 72 , 73 ).”
Programmed cell death protein 1 on natural killer cells: fact or fiction?
Cho, M. M., Quamine, A. E., Olsen, M. R., & Capitini, C. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137051 · Cited by 13
Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors
Yuan, W., Xiao, C., Lao, X., Zheng, L., & Kuang, D. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03637-1 · Cited by 14
Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity
Mendoza, A., Álvarez, M., Maria, A. D., Margolin, K. A., Melero, I., & Ascierto, M. L. (2022) · Cells · doi:10.3390/cells11193147 · Cited by 15
“However, several studies are now emerging which show an expression of PD1 not only on T cells, but also on additional immune cells, including NK cells [43,44] and B cells [45–47].”
BackgroundHarnessing NK Cells to Control Metastasis
Deng, X., & Terunuma, H. (2022) · Vaccines · doi:10.3390/vaccines10122018 · Cited by 13
“However, the effect of ICIs on NK cells through PD-1/PD-L1 blockade also mediates antitumor immunity [9].”
BackgroundApplication status and future prospects of the PDX model in lung cancer
Liu, W., Cui, Y., Zheng, X., Yu, K., & Sun, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1098581 · Cited by 14
“Programmed death ligand 1 (PD-L1) is present on the surface of tumor cells and inhibits the activation and proliferation of T cells, which results in immune escape of tumor cells by specifically binding the programmed death receptor-1 (PD1) (58, 59).”
BackgroundMachado, F. C., Girola, N., Maia, V., Bergami-Santos, P. C., Morais, A. S., Azevedo, R., Figueiredo, C. R., Barbuto, J. A. M., & Travassos, L. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03122 · Cited by 13
“In the NK cell population, PD-1 blockade immunotherapy can activate those cells to infiltrate melanoma and lung tumors to elicit anti-tumor responses (57, 58).”
BackgroundImproved Efficacy of Antibody Cancer Immunotherapeutics through Local and Sustained Delivery
Huynh, V. A., Jesmer, A. H., Shoaib, M. M., D'Angelo, A. D., Rullo, A. F., & Wylie, R. G. (2018) · ChemBioChem · doi:10.1002/cbic.201800579 · Cited by 14
Combining radiotherapy and NK cell-based therapies: The time has come
Baude, J., Limagne, E., Ladjohounlou, R., & Mirjolet, C. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.02.003 · Cited by 14
Controlling viral inflammatory lesions by rebalancing immune response patterns
Mulik, S., Berber, E., Sehrawat, S., & Rouse, B. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257192 · Cited by 13
Sánchez, M. B., Cordoba, B. V., Pavlovsky, C., Moiraghi, B., Varela, A. I., Custidiano, R., Fernandez, I. I., Freitas, M. J., Ventriglia, V., Bendek, G. E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1241600 · Cited by 13
Montagner, A., Arleo, A., Suzzi, F., D’Assoro, A. B., Piscaglia, F., Gramantieri, L., & Giovannini, C. (2024) · Biomolecules · doi:10.3390/biom14121581 · Cited by 13
Chajuwan, T., Kansuwan, P., Kobbuaklee, S., & Chanswangphuwana, C. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1984454 · Cited by 13
“Increasing evidence of PD-1 expression on NK cell encourages the role of PD-1/PD-L1 blockade for targeting both T and NK cell dysfunction in cancer [42,43].”
BackgroundBack to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function
Li, J. H., & O’Sullivan, T. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816658 · Cited by 12
NK cell dysfunction is linked with disease severity in SARS‐CoV‐2 patients
Asl, K. D., Mazloumi, Z., Majidi, G., Kalarestaghi, H., Sabetkam, S., & Rafat, A. (2022) · Cell Biochemistry and Function · doi:10.1002/cbf.3725 · Cited by 12
“The interaction of PD‐1–PD‐L1 inhibit NK cell‐mediated antitumor immunity.(74) The presence of NK cells expressing PD‐1 was reported in Kaposi sarcoma or ovarian carcinoma patients.”
BackgroundQiu, Z., Zhao, L., Liu, X., Zhang, R., Li, Y., Gao, C., Mao, X., Bao, Y., Zhang, M., & Guo, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1478922 · Cited by 12
Metadata
- Authors
- Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., Zhang, L., Iannello, A., Mathur, N., Jardine, K. E., Kirn, G. A., Bell, J. C., McBurney, M. W., Raulet, D. H., & Ardolino, M.
- Affiliations
- University of California, Berkeley (US)
- University of Ottawa (CA)
- Corresponding author
- Raulet, David H.
- Ardolino, Michele
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-09-10
- Volume
- 128
- Issue
- 10
- Pages
- 4654-4668
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6159991
- OpenAlex
- W2890056446
- Cited by
- 817
- References
- 82
- Citations by year
- 2026: 57 · 2025: 96 · 2024: 107 · 2023: 101 · 2022: 106 · 2021: 148 · 2020: 124 · 2019: 68 · 2018: 7
- FWCI
- 37.29
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA093678)
- National Institute of General Medical Sciences (T32GM007232)
- National Institute of Allergy and Infectious Diseases (R01AI113041)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- natural killer cells, PD-1, PD-L1, immune checkpoint blockade, cancer immunotherapy, NK cell exhaustion, antitumor immunity, NK cell activation, tumor immunosuppression, MHC expression
- MeSH terms
- Animals, Humans, Immunotherapy, Killer Cells, Natural, Neoplasms, Experimental, Mice, Knockout, K562 Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.